SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic
The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regio...
Saved in:
Published in | Viruses Vol. 13; no. 8; p. 1648 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel
MDPI AG
19.08.2021
MDPI |
Subjects | |
Online Access | Get full text |
ISSN | 1999-4915 1999-4915 |
DOI | 10.3390/v13081648 |
Cover
Loading…
Abstract | The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the “ELISA anti-SARS-CoV-2 IgG” reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer’s instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1–17, 18–29, 30–39, 40–49, 59–59, 60–69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8–23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1–31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8–21.1) to 18.0% (IQR: 13.4–22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1–94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity. |
---|---|
AbstractList | The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the “ELISA anti-SARS-CoV-2 IgG” reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer’s instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1–17, 18–29, 30–39, 40–49, 59–59, 60–69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8–23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1–31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8–21.1) to 18.0% (IQR: 13.4–22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1–94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity. The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the "ELISA anti-SARS-CoV-2 IgG" reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer's instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1-17, 18-29, 30-39, 40-49, 59-59, 60-69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8-23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1-31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8-21.1) to 18.0% (IQR: 13.4-22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1-94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the "ELISA anti-SARS-CoV-2 IgG" reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer's instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1-17, 18-29, 30-39, 40-49, 59-59, 60-69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8-23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1-31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8-21.1) to 18.0% (IQR: 13.4-22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1-94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity. |
Author | Bulanov, Maxim V. Noskov, Alexei K. Penkovskaya, Natalia A. Detkovskaya, Tatyana N. Smirnov, Viacheslav S. Vetrov, Viacheslav. V. Valeullina, Natalia. N. Melnikova, Albina. A. Mikailova, Olga M. Balakhonov, Sergey V. Popova, Anna Y. Istorik, Olga A. Bashketova, Natalia S. Lukicheva, Lena A. Stepanova, Tatyana F. Trotsenko, Olga E. Lomovtsev, Alexander. E. Lyalina, Ludmila V. Noskova, Ludmila N. Kovalchuk, Irina. V. Samoilova, Lada V. Kombarova, Svetlana Y. Patyashina, Marina A. Kozlovskikh, Dmitriy N. Babura, Elena A. Zaitseva, Natalia N. Andreeva, Elena E. Totolian, Areg A. Kurganova, Olga. P. Osmolovskaya, Tatyana P. Bugorkova, Svetlana A. Ezhlova, Elena B. Goryaev, Dmitriy. V. Oglezneva, Elena E. |
AuthorAffiliation | 29 Khabarovsk Research Institute of Epidemiology and Microbiology, 680000 Khabarovsk, Russia; trotsenko_oe@hniiem.ru 2 Saint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia; vvv-3@bk.ru (V.V.V.); lyalina@pasteurorg.ru (L.V.L.); pasteur@pasteurorg.ru (A.A.T.) 10 Rospotrebnadzor Administration in the Krasnoyarsk Territory, 660049 Krasnoyarsk, Russia; goryaev_dv@24.rospotrebnadzor.ru 8 Center for Hygiene and Epidemiology of the Vladimir Region, 600005 Vladimir, Russia; sgm@vladses.vladinfo.ru 14 Rospotrebnadzor Administration in the Stavropol Territory, 355008 Stavropol, Russia; Kovalchuk_IV@26.rospotrebnadzor.ru 17 Rospotrebnadzor Administration in the Amur Region, 675002 Blagoveshchensk, Russia; info@rospotrebnadzor-amur.ru 21 Rostov-on-Don Research Anti-Plague Institute, 344000 Rostov-on-Don, Russia; noskov-epid@mai.ru 1 Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia; anna.popova.00.00@mail.ru (A.Y.P.); ezhlova_eb@rospotrebna |
AuthorAffiliation_xml | – name: 28 Tyumen Research Institute of Regional Infectious Pathology, 625026 Tyumen, Russia; StepanovaTF@Tniikip.rospotrebnadzor.ru – name: 18 Rospotrebnadzor Administration in the Tula Region, 300045 Tula, Russia; tula@71.rospotrebnadzor.ru – name: 24 Rospotrebnadzor Administration in the Krasnodar Territory, 350000 Krasnodar, Russia; gorses@mail.kuban.ru – name: 13 Rospotrebnadzor Administration in the Leningrad Region, 192029 St. Petersburg, Russia; lenobl@47.rospotrebnadzor.ru – name: 5 Irkutsk Research Anti-Plague Institute, 664047 Irkutsk, Russia; adm@chumin.irkutsk.ru – name: 22 Rospotrebnadzor Administration for the Astrakhan Region, 414057 Astrakhan, Russia; tu_rpn@astrakhan.ru – name: 29 Khabarovsk Research Institute of Epidemiology and Microbiology, 680000 Khabarovsk, Russia; trotsenko_oe@hniiem.ru – name: 26 Rospotrebnadzor Administration in the Republic of Crimea, 295034 Simferopol, Russia; crimea@82.rospotrebnadzor.ru – name: 2 Saint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia; vvv-3@bk.ru (V.V.V.); lyalina@pasteurorg.ru (L.V.L.); pasteur@pasteurorg.ru (A.A.T.) – name: 8 Center for Hygiene and Epidemiology of the Vladimir Region, 600005 Vladimir, Russia; sgm@vladses.vladinfo.ru – name: 14 Rospotrebnadzor Administration in the Stavropol Territory, 355008 Stavropol, Russia; Kovalchuk_IV@26.rospotrebnadzor.ru – name: 11 Rospotrebnadzor Administration in the Primorsky Krai, 690950 Vladivostok, Russia; Detkovskaya_TN@pkrpn.ru – name: 1 Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia; anna.popova.00.00@mail.ru (A.Y.P.); ezhlova_eb@rospotrebnadzor.ru (E.B.E.); melnikova_aa@rospotrebnadzor.ru (A.A.M.) – name: 7 Russian Research Anti-Plague Institute “Microbe”, 410005 Saratov, Russia; bugorkova29@mail.ru – name: 21 Rostov-on-Don Research Anti-Plague Institute, 344000 Rostov-on-Don, Russia; noskov-epid@mai.ru – name: 25 Rospotrebnadzor Administration in the Republic of Tatarstan, 420111 Kazan, Russia; org@16.rospotrebnadzor.ru – name: 12 Nizhny Novgorod I. N. Blokhina Research Institute of Epidemiology and Microbiology, 603950 Nizhny Novgorod, Russia; vtashca@mail.ru – name: 27 Rospotrebnadzor Administration in the Novosibirsk Region, 630132 Novosibirsk, Russia; epid@54rospotrebnadzor.ru – name: 9 Rospotrebnadzor Administration in the Chelyabinsk Region, 454091 Chelyabinsk, Russia; ValeullinaNN@chel.surpet.ru – name: 20 Rospotrebnadzor Administration in the Moscow Region, 141014 Mytishchi, Moscow Region, Russia; org@50.rospotrebnadzor.ru – name: 3 Rospotrebnadzor Administration in Moscow, 129626 Moscow, Russia; uprav@77.rospotrebnadzor.ru – name: 10 Rospotrebnadzor Administration in the Krasnoyarsk Territory, 660049 Krasnoyarsk, Russia; goryaev_dv@24.rospotrebnadzor.ru – name: 6 Rospotrebnadzor Administration in St. Petersburg, 191025 St. Petersburg, Russia; nbashketova@gmail.com – name: 17 Rospotrebnadzor Administration in the Amur Region, 675002 Blagoveshchensk, Russia; info@rospotrebnadzor-amur.ru – name: 4 Rospotrebnadzor Administration in the Kaliningrad Region, 236040 Kaliningrad, Russia; elena_babura@mail.ru – name: 19 Rospotrebnadzor Administration in the Murmansk Region, 183038 Murmansk, Russia; lukichevalena@icloud.com – name: 23 Rospotrebnadzor Administration in the Belgorod Region, 308023 Belgorod, Russia; orgotd@31rospotrebnadzor.ru – name: 15 Rospotrebnadzor Administration in the Sverdlovsk Region, 620078 Yekaterinburg, Russia; Kozlovskih_DN@66rospotrebnadzor.ru – name: 16 G. N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, 125212 Moscow, Russia; kombarova311@bk.ru |
Author_xml | – sequence: 1 givenname: Anna Y. surname: Popova fullname: Popova, Anna Y. – sequence: 2 givenname: Viacheslav S. orcidid: 0000-0002-2723-1496 surname: Smirnov fullname: Smirnov, Viacheslav S. – sequence: 3 givenname: Elena E. surname: Andreeva fullname: Andreeva, Elena E. – sequence: 4 givenname: Elena A. surname: Babura fullname: Babura, Elena A. – sequence: 5 givenname: Sergey V. surname: Balakhonov fullname: Balakhonov, Sergey V. – sequence: 6 givenname: Natalia S. surname: Bashketova fullname: Bashketova, Natalia S. – sequence: 7 givenname: Svetlana A. surname: Bugorkova fullname: Bugorkova, Svetlana A. – sequence: 8 givenname: Maxim V. surname: Bulanov fullname: Bulanov, Maxim V. – sequence: 9 givenname: Natalia. N. surname: Valeullina fullname: Valeullina, Natalia. N. – sequence: 10 givenname: Viacheslav. V. surname: Vetrov fullname: Vetrov, Viacheslav. V. – sequence: 11 givenname: Dmitriy. V. surname: Goryaev fullname: Goryaev, Dmitriy. V. – sequence: 12 givenname: Tatyana N. surname: Detkovskaya fullname: Detkovskaya, Tatyana N. – sequence: 13 givenname: Elena B. surname: Ezhlova fullname: Ezhlova, Elena B. – sequence: 14 givenname: Natalia N. surname: Zaitseva fullname: Zaitseva, Natalia N. – sequence: 15 givenname: Olga A. surname: Istorik fullname: Istorik, Olga A. – sequence: 16 givenname: Irina. V. surname: Kovalchuk fullname: Kovalchuk, Irina. V. – sequence: 17 givenname: Dmitriy N. surname: Kozlovskikh fullname: Kozlovskikh, Dmitriy N. – sequence: 18 givenname: Svetlana Y. surname: Kombarova fullname: Kombarova, Svetlana Y. – sequence: 19 givenname: Olga. P. surname: Kurganova fullname: Kurganova, Olga. P. – sequence: 20 givenname: Alexander. E. surname: Lomovtsev fullname: Lomovtsev, Alexander. E. – sequence: 21 givenname: Lena A. surname: Lukicheva fullname: Lukicheva, Lena A. – sequence: 22 givenname: Ludmila V. surname: Lyalina fullname: Lyalina, Ludmila V. – sequence: 23 givenname: Albina. A. surname: Melnikova fullname: Melnikova, Albina. A. – sequence: 24 givenname: Olga M. surname: Mikailova fullname: Mikailova, Olga M. – sequence: 25 givenname: Alexei K. surname: Noskov fullname: Noskov, Alexei K. – sequence: 26 givenname: Ludmila N. surname: Noskova fullname: Noskova, Ludmila N. – sequence: 27 givenname: Elena E. surname: Oglezneva fullname: Oglezneva, Elena E. – sequence: 28 givenname: Tatyana P. surname: Osmolovskaya fullname: Osmolovskaya, Tatyana P. – sequence: 29 givenname: Marina A. surname: Patyashina fullname: Patyashina, Marina A. – sequence: 30 givenname: Natalia A. surname: Penkovskaya fullname: Penkovskaya, Natalia A. – sequence: 31 givenname: Lada V. surname: Samoilova fullname: Samoilova, Lada V. – sequence: 32 givenname: Tatyana F. surname: Stepanova fullname: Stepanova, Tatyana F. – sequence: 33 givenname: Olga E. surname: Trotsenko fullname: Trotsenko, Olga E. – sequence: 34 givenname: Areg A. surname: Totolian fullname: Totolian, Areg A. |
BookMark | eNqFkktrGzEURoeS0jzaRf_BQDftYhq9ZW0KwX0ZAglxm0U34lq648iMJUeaMfTfd2yH0IRCVxK6Rwd9uve0OoopYlW9peQj54acbyknE6rE5EV1Qo0xjTBUHv21P65OS1kRopQh-lV1zIWQTFJ2Uv2aX9zMm2m6bVg9x5w2GbfQYXRYz_s8uH7IWKe27u-wvhlKCRDr67QZOuhDirUfcojLfXV6dTv73FBTX0P0uA7udfWyha7gm4f1rPr59cuP6ffm8urbbHpx2TihTd8gKFggRUolNdgiR6Wdb4lErg2DVjtUjIL3oLUHtpBG0IlnHluNqpWMn1Wzg9cnWNlNDmvIv22CYPcHKS8t5D64Dq03SnLDFDhGhPdsIrkGQqH1YkEoktH16eDaDIs1eoexz9A9kT6txHBnl2lrJ4IwLekoeP8gyOl-wNLbdSgOuw4ipqFYprjSQjGp_o9KpYgYe7iL-O4ZukpDjuOv7iipxzRmJ_xwoFxOpWRsH99Nid0Nin0clJE9f8a60O97OsYK3T9u_AF-ub6t |
CitedBy_id | crossref_primary_10_1080_23744235_2023_2179660 crossref_primary_10_31631_2073_3046_2024_23_4_12_22 crossref_primary_10_15789_1563_0625_PVI_2457 crossref_primary_10_1016_j_abst_2025_03_001 crossref_primary_10_3390_v15102014 crossref_primary_10_3390_vaccines13030249 crossref_primary_10_51350_zdravkg_2023_11_61_001 crossref_primary_10_3390_ijerph19042263 crossref_primary_10_31631_2073_3046_2022_21_1_81_91 crossref_primary_10_15789_2220_7619_MFA_1770 crossref_primary_10_3390_v15112181 crossref_primary_10_4103_OJMR_OJMR_12_23 crossref_primary_10_1007_s12519_022_00617_2 crossref_primary_10_1093_ofid_ofad614 crossref_primary_10_3390_v14050913 crossref_primary_10_15789_2220_7619_HIT_1798 crossref_primary_10_7189_jogh_13_06004 crossref_primary_10_15789_1563_0625_PIT_2867 crossref_primary_10_1016_j_envres_2022_114655 crossref_primary_10_3390_v14050941 crossref_primary_10_22625_2072_6732_2021_13_4_79_89 crossref_primary_10_21886_2219_8075_2022_13_2_199_216 crossref_primary_10_1371_journal_pone_0311287 crossref_primary_10_15789_1563_0625_MOF_2490 |
Cites_doi | 10.21055/0370-1069-2020-3-114-123 10.1016/S0140-6736(21)00183-5 10.1016/j.medj.2020.10.003 10.1172/jci.insight.142386 10.21055/0370-1069-2020-3-124-130 10.1126/science.abj3858 10.36233/0372-9311-92 10.3389/fcell.2020.547314 10.1016/j.cell.2020.09.038 10.20953/1729-9225-2020-4-17-26 10.1126/science.abe1107 10.1001/jamanetworkopen.2021.4302 10.1001/jama.2020.8707 10.3390/v13010029 10.3201/eid2705.204365 10.1016/j.jinf.2020.03.027 10.1007/s15010-021-01629-2 10.3201/eid2609.201840 10.24110/0031-403X-2021-100-3-97-106 10.7554/eLife.63537 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E 10.1001/jama.2020.8279 10.3390/vaccines8020236 10.1002/jnr.24752 10.1016/j.xcrm.2021.100313 10.1016/S0140-6736(21)00238-5 10.1136/bmjopen-2020-045425 10.2807/1560-7917.ES.2020.25.16.2000421 10.22625/2072-6732-2020-12-5-62-71 10.36233/0372-9311-2020-97-6-2 10.4103/ijmr.IJMR_977_20 10.21055/0370-1069-2020-3-106-113 10.1016/j.jcv.2020.104683 10.1001/jamainternmed.2020.4130 10.1126/science.abc6810 10.1016/j.immuni.2020.04.012 10.1101/2020.07.18.20155374 10.1016/j.jhin.2020.11.008 10.1016/j.pcl.2020.07.014 10.1016/j.immuni.2020.05.002 10.3389/fped.2021.619738 10.1038/s41591-020-0949-6 10.1016/j.cmi.2020.10.020 10.3389/fimmu.2020.586781 10.3389/fimmu.2021.631139 10.1002/ppul.24981 10.3346/jkms.2020.35.e333 10.1038/s41591-020-0965-6 10.1016/S1473-3099(20)30858-6 10.5694/mja2.50940 10.1002/cti2.1136 10.1101/2020.04.25.20079103 10.20953/1729-9225-2020-4-8-16 10.1038/s41581-020-00357-4 10.1038/s41591-020-0913-5 10.36233/0372-9311-2020-97-5-1 |
ContentType | Journal Article |
Copyright | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 by the authors. 2021 |
Copyright_xml | – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 by the authors. 2021 |
DBID | AAYXX CITATION 3V. 7U9 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM DOA |
DOI | 10.3390/v13081648 |
DatabaseName | CrossRef ProQuest Central (Corporate) Virology and AIDS Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection (ProQuest) Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | AGRICOLA Publicly Available Content Database MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1999-4915 |
ExternalDocumentID | oai_doaj_org_article_d9653926ac204dd28537a01afd4b01e0 PMC8402751 10_3390_v13081648 |
GeographicLocations | Russia |
GeographicLocations_xml | – name: Russia |
GroupedDBID | --- 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABUWG ACUHS AFKRA AFPKN AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION DIK E3Z EBD ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M48 M7P MODMG M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RPM TR2 TUS UKHRP 3V. 7U9 7XB 8FK AZQEC COVID DWQXO GNUQQ H94 K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 7S9 L.6 5PM PUEGO |
ID | FETCH-LOGICAL-c479t-ea6abe1e11519efe3e67cdf05e3792af7ce621adda77da2b59418d2def7e6f523 |
IEDL.DBID | DOA |
ISSN | 1999-4915 |
IngestDate | Wed Aug 27 01:31:08 EDT 2025 Thu Aug 21 18:34:45 EDT 2025 Fri Jul 11 02:27:19 EDT 2025 Mon Jul 21 09:49:37 EDT 2025 Fri Jul 25 09:59:16 EDT 2025 Tue Jul 01 02:48:26 EDT 2025 Thu Apr 24 22:58:22 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c479t-ea6abe1e11519efe3e67cdf05e3792af7ce621adda77da2b59418d2def7e6f523 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-2723-1496 |
OpenAccessLink | https://doaj.org/article/d9653926ac204dd28537a01afd4b01e0 |
PMID | 34452512 |
PQID | 2565720496 |
PQPubID | 2032319 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d9653926ac204dd28537a01afd4b01e0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8402751 proquest_miscellaneous_2636746256 proquest_miscellaneous_2566041992 proquest_journals_2565720496 crossref_primary_10_3390_v13081648 crossref_citationtrail_10_3390_v13081648 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20210819 |
PublicationDateYYYYMMDD | 2021-08-19 |
PublicationDate_xml | – month: 8 year: 2021 text: 20210819 day: 19 |
PublicationDecade | 2020 |
PublicationPlace | Basel |
PublicationPlace_xml | – name: Basel |
PublicationTitle | Viruses |
PublicationYear | 2021 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Popova (ref_29) 2020; 4 ref_50 Kwok (ref_45) 2020; 80 Popova (ref_23) 2020; 3 Popova (ref_28) 2020; 18 Popova (ref_24) 2020; 97 Popova (ref_22) 2021; 100 Shiakolas (ref_42) 2021; 2 ref_53 Popova (ref_31) 2021; 11 Hippich (ref_44) 2021; 2 Hou (ref_49) 2020; 9 ref_16 ref_15 Vabret (ref_8) 2020; 52 Grant (ref_60) 2021; 11 Kuttiatt (ref_13) 2020; 152 Williams (ref_43) 2020; 52 Popova (ref_17) 2021; 11 Yang (ref_36) 2021; 4 Moderbacher (ref_39) 2020; 183 ref_67 Uversky (ref_3) 2020; 99 Balicer (ref_10) 2021; 37 Jeremijenko (ref_62) 2021; 27 Britton (ref_70) 2020; 369 Perico (ref_2) 2020; 17 Amanat (ref_12) 2020; 26 Goyal (ref_52) 2021; 10 Grzhibovsky (ref_21) 2008; 5 Pujari (ref_5) 2020; 12 Popova (ref_32) 2021; 13 Sood (ref_35) 2020; 323 Popova (ref_26) 2020; 12 Reicher (ref_69) 2021; 2021 Bunyavanich (ref_40) 2020; 323 Randolph (ref_7) 2020; 52 Poustchi (ref_63) 2021; 21 Popova (ref_33) 2020; 97 Newcombe (ref_34) 1998; 17 Han (ref_37) 2021; 9 Havers (ref_64) 2020; 180 Kuznik (ref_38) 2020; 33 Long (ref_55) 2020; 26 Popova (ref_18) 2020; 3 Perera (ref_58) 2020; 25 Chen (ref_47) 2021; 9 Tsabouri (ref_68) 2021; 68 Gidding (ref_66) 2021; 214 Popova (ref_27) 2020; 18 Fialkowski (ref_51) 2020; 55 Popova (ref_19) 2020; 3 Vignesh (ref_11) 2020; 11 Agresti (ref_20) 1998; 52 Khoshchehreh (ref_56) 2020; 133 Rostami (ref_9) 2020; 27 Jeong (ref_54) 2020; 35 Popova (ref_25) 2020; 4 ref_41 Triggle (ref_48) 2021; 12 Galanis (ref_46) 2021; 108 ref_1 He (ref_14) 2021; 397 Popova (ref_30) 2021; 98 Xia (ref_59) 2020; 8 McAndrews (ref_57) 2020; 5 Xu (ref_61) 2020; 26 ref_4 Sabino (ref_65) 2021; 397 ref_6 |
References_xml | – volume: 3 start-page: 114 year: 2020 ident: ref_18 article-title: Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii] doi: 10.21055/0370-1069-2020-3-114-123 – volume: 397 start-page: 452 year: 2021 ident: ref_65 article-title: Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence publication-title: Lancet doi: 10.1016/S0140-6736(21)00183-5 – volume: 2 start-page: 149 year: 2021 ident: ref_44 article-title: A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children publication-title: Med. doi: 10.1016/j.medj.2020.10.003 – volume: 5 start-page: e142386 year: 2020 ident: ref_57 article-title: Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity publication-title: JCI Insight doi: 10.1172/jci.insight.142386 – volume: 3 start-page: 124 year: 2020 ident: ref_19 article-title: Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic publication-title: Probl. Osob. Opasnykh Infektsii [Probl. Part. Danger. Infect.] doi: 10.21055/0370-1069-2020-3-124-130 – volume: 37 start-page: 663 year: 2021 ident: ref_10 article-title: Israel’s COVID-19 endgame publication-title: Science doi: 10.1126/science.abj3858 – volume: 98 start-page: 7 year: 2021 ident: ref_30 article-title: The seroprevalence of SARS-CoV-2 among residents of the Khabarovsk Krai during the COVID-19 epidemic publication-title: J. Microbiol. Epidemiol. Immunobiol. [Zhurnal Mikrobiol. Èpidemiologii I Immunobiol.] doi: 10.36233/0372-9311-92 – ident: ref_16 – volume: 8 start-page: 547314 year: 2020 ident: ref_59 article-title: How to Understand “Herd Immunity” in COVID-19 Pandemic publication-title: Front. Cell. Dev. Biol. doi: 10.3389/fcell.2020.547314 – volume: 13 start-page: 17 year: 2021 ident: ref_32 article-title: Humoral immunity to SARS-CoV-2 among the population of Murmansk region amid COVID-19 epidemic publication-title: HIV Infect. Immunosuppr. – volume: 183 start-page: 996 year: 2020 ident: ref_39 article-title: Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity publication-title: Cell doi: 10.1016/j.cell.2020.09.038 – volume: 9 start-page: e598 year: 2021 ident: ref_47 article-title: Serological evidence of human infection with SARS-CoV-2: A systematic review and meta-analysis Lancet Glob publication-title: Health – volume: 18 start-page: 17 year: 2020 ident: ref_28 article-title: The structure of seroprevalence to the SARS-CoV-2 virus among residents of the Moscow Region during the period of epidemic incidence of COVID-19 publication-title: Infekc. Bolezn. [Infect. Dis.] doi: 10.20953/1729-9225-2020-4-17-26 – ident: ref_41 doi: 10.1126/science.abe1107 – volume: 4 start-page: e214302 year: 2021 ident: ref_36 article-title: Association of Age With SARS-CoV-2 Antibody Response publication-title: JAMA Netw Open. doi: 10.1001/jamanetworkopen.2021.4302 – ident: ref_1 – volume: 323 start-page: 2427 year: 2020 ident: ref_40 article-title: Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults publication-title: JAMA doi: 10.1001/jama.2020.8707 – ident: ref_4 doi: 10.3390/v13010029 – volume: 27 start-page: 1343 year: 2021 ident: ref_62 article-title: Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2705.204365 – volume: 80 start-page: e32 year: 2020 ident: ref_45 article-title: Herd immunity—Estimating the level required to halt the COVID-19 epidemics in affected countries publication-title: J. Infect. doi: 10.1016/j.jinf.2020.03.027 – ident: ref_67 doi: 10.1007/s15010-021-01629-2 – ident: ref_15 doi: 10.3201/eid2609.201840 – volume: 100 start-page: 97 year: 2021 ident: ref_22 article-title: Peculiarities of seroprevalence to nucleocapsid SARS-CoV-2 in children during the 2020 COVID-19 epidemic publication-title: Pediatric doi: 10.24110/0031-403X-2021-100-3-97-106 – volume: 10 start-page: e63537 year: 2021 ident: ref_52 article-title: Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events publication-title: eLife doi: 10.7554/eLife.63537 – volume: 17 start-page: 857 year: 1998 ident: ref_34 article-title: Two-sided confidence intervals for the single proportion: Comparison of seven methods publication-title: Stat. Med. doi: 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E – volume: 4 start-page: 117 year: 2020 ident: ref_25 article-title: Assessment of Population Immunity to SARS-CoV-2 Virus in the Rostov Region publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii] – volume: 52 start-page: 119 year: 1998 ident: ref_20 article-title: Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions publication-title: Am. Stat. – volume: 323 start-page: 2425 year: 2020 ident: ref_35 article-title: Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10–11, 2020 publication-title: JAMA doi: 10.1001/jama.2020.8279 – ident: ref_6 doi: 10.3390/vaccines8020236 – volume: 99 start-page: 750 year: 2020 ident: ref_3 article-title: Severe acute respiratory syndrome coronavirus 2 infection reaches the human nervous system: How? publication-title: J. Neurosci. Res. doi: 10.1002/jnr.24752 – volume: 11 start-page: 29 year: 2021 ident: ref_31 article-title: Analysis of SARS-CoV-2 seroprevalence among the population of the Vladimir Region during the COVID-19 epidemic. Epidemiology and infectious diseases publication-title: Curr. Items – volume: 2 start-page: 100313 year: 2021 ident: ref_42 article-title: Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2021.100313 – volume: 397 start-page: 1075 year: 2021 ident: ref_14 article-title: Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: A longitudinal, population-level, cross-sectional study publication-title: Lancet doi: 10.1016/S0140-6736(21)00238-5 – volume: 11 start-page: e045425 year: 2021 ident: ref_60 article-title: SARS-CoV-2 population-based seroprevalence studies in Europe: A scoping review publication-title: BMJ Open doi: 10.1136/bmjopen-2020-045425 – volume: 25 start-page: 2000421 year: 2020 ident: ref_58 article-title: Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2020.25.16.2000421 – volume: 12 start-page: 62 year: 2020 ident: ref_26 article-title: Population immunity to SARS-CoV-2 of the population of the Kaliningrad region during the epidemic season of COVID-19 publication-title: J. Infectology [Zhurnal Infektologii] doi: 10.22625/2072-6732-2020-12-5-62-71 – volume: 97 start-page: 518 year: 2020 ident: ref_33 article-title: Distribution of SARS-CoV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period publication-title: J. Microbiol. Epidemiol. Immunobiol. [Zhurnal Mikrobiol. Èpidemiologii I Immunobiologii] doi: 10.36233/0372-9311-2020-97-6-2 – volume: 152 start-page: 21 year: 2020 ident: ref_13 article-title: Coronavirus disease 2019 in children: Clinical & epidemiological implications publication-title: Indian J. Med. Res. doi: 10.4103/ijmr.IJMR_977_20 – volume: 33 start-page: 1032 year: 2020 ident: ref_38 article-title: Features of pathogenesis and COVID-19 course for the elderly and old age publication-title: Adv. Geront. – volume: 3 start-page: 106 year: 2020 ident: ref_23 article-title: Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii] doi: 10.21055/0370-1069-2020-3-106-113 – volume: 2021 start-page: 1 year: 2021 ident: ref_69 article-title: Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel publication-title: Eur. J. Epidemiol. – volume: 12 start-page: e10480 year: 2020 ident: ref_5 article-title: Therapeutic Options for COVID-19: A Review publication-title: Cureus – volume: 133 start-page: 104683 year: 2020 ident: ref_56 article-title: A needle in the haystack? Assessing the significance of envelope (E) gene-negative, nucleocapsid (N2) gene-positive SARS-CoV-2 detection by the Cepheid Xpert Xpress SARS-COV-2 assay publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2020.104683 – volume: 180 start-page: 1576 year: 2020 ident: ref_64 article-title: Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23 May 12, 2020 publication-title: JAMA Intern. Med. doi: 10.1001/jamainternmed.2020.4130 – volume: 4 start-page: 106 year: 2020 ident: ref_29 article-title: Characteristics of the Herd Immunity to SARS-CoV-2 in Residents of the Saratov Region under COVID-19 Epidemic publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii] doi: 10.21055/0370-1069-2020-3-106-113 – volume: 369 start-page: 846 year: 2020 ident: ref_70 article-title: A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2 publication-title: Science doi: 10.1126/science.abc6810 – volume: 52 start-page: 737 year: 2020 ident: ref_7 article-title: Herd Immunity: Understanding COVID-19 publication-title: Immunity doi: 10.1016/j.immuni.2020.04.012 – ident: ref_50 doi: 10.1101/2020.07.18.20155374 – volume: 5 start-page: 57 year: 2008 ident: ref_21 article-title: Confidence intervals for frequencies and beats publication-title: Hum. Ecol. – volume: 108 start-page: 120 year: 2021 ident: ref_46 article-title: Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: A systematic review and meta-analysis publication-title: J. Hosp. Infect. doi: 10.1016/j.jhin.2020.11.008 – volume: 68 start-page: 321 year: 2021 ident: ref_68 article-title: Risk Factors for Severity in Children with Coronavirus Disease 2019. A Comprehensive Literature Review publication-title: Pediatr. Clin. N. Am. doi: 10.1016/j.pcl.2020.07.014 – volume: 52 start-page: 910 year: 2020 ident: ref_8 article-title: The Sinai Immunology Review Project. Immunology of COVID-19: Current state of the science publication-title: Immunity doi: 10.1016/j.immuni.2020.05.002 – volume: 9 start-page: 619738 year: 2021 ident: ref_37 article-title: Distinct Characteristics of COVID-19 Infection in Children publication-title: Front. Pediatr. doi: 10.3389/fped.2021.619738 – volume: 52 start-page: 801 year: 2020 ident: ref_43 article-title: SARS-CoV-2 in children: Spectrum of disease, transmission and immunopathological underpinnings publication-title: Pathol. – volume: 26 start-page: 1193 year: 2020 ident: ref_61 article-title: Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China publication-title: Nat. Med. doi: 10.1038/s41591-020-0949-6 – volume: 27 start-page: 331 year: 2020 ident: ref_9 article-title: SARS-CoV-2 seroprevalence worldwide: A systematic review and meta-analysis publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2020.10.020 – volume: 11 start-page: 586781 year: 2020 ident: ref_11 article-title: Is Herd Immunity Against SARS-CoV-2 a Silver Lining? publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.586781 – volume: 11 start-page: 297 year: 2021 ident: ref_17 article-title: Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation publication-title: Russ. J. Infect. Immun. [Infektsiya I Immun.] – volume: 12 start-page: 631139 year: 2021 ident: ref_48 article-title: A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.631139 – volume: 55 start-page: 2556 year: 2020 ident: ref_51 article-title: Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection publication-title: Pediatric Pulmonol. doi: 10.1002/ppul.24981 – volume: 35 start-page: e333 year: 2020 ident: ref_54 article-title: Real Asymptomatic SARS-CoV-2 Infection Might Be Rare: Importance of Careful Interviews and Follow-up publication-title: J. Korean Med. Sci. doi: 10.3346/jkms.2020.35.e333 – volume: 26 start-page: 1200 year: 2020 ident: ref_55 article-title: Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections publication-title: Nat. Med. doi: 10.1038/s41591-020-0965-6 – volume: 21 start-page: 473 year: 2021 ident: ref_63 article-title: SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: A population-based cross-sectional study publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30858-6 – volume: 214 start-page: 179 year: 2021 ident: ref_66 article-title: Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020 publication-title: Med. J. Aust. doi: 10.5694/mja2.50940 – volume: 9 start-page: e01136 year: 2020 ident: ref_49 article-title: Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 publication-title: Clin. Transl. Immunol. doi: 10.1002/cti2.1136 – ident: ref_53 doi: 10.1101/2020.04.25.20079103 – volume: 18 start-page: 8 year: 2020 ident: ref_27 article-title: Collective immunity to SARS-CoV-2 of Moscow residents during the COVID-19 epidemic period publication-title: Infekc. Bolezn. [Infect. Dis.] doi: 10.20953/1729-9225-2020-4-8-16 – volume: 17 start-page: 46 year: 2020 ident: ref_2 article-title: Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 publication-title: Nat. Rev. Nephrol. doi: 10.1038/s41581-020-00357-4 – volume: 26 start-page: 1033 year: 2020 ident: ref_12 article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans publication-title: Nat. Med. doi: 10.1038/s41591-020-0913-5 – volume: 97 start-page: 392 year: 2020 ident: ref_24 article-title: Distribution of SARS-CoV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period publication-title: J. Microbiol. Epidemiol. Immunobiol. {Zhurnal Mikrobiol. Èpidemiologii I Immunobiol.] doi: 10.36233/0372-9311-2020-97-5-1 |
SSID | ssj0066907 |
Score | 2.3925776 |
Snippet | The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1648 |
SubjectTerms | Adaptive immunity Age Antibodies antigens Asymptomatic asymptomatic form Biotechnology cohort studies Coronaviruses COVID-19 COVID-19 infection COVID-19 vaccines Disease transmission Herd immunity Immunoglobulin G Infections Influenza Medical research Morbidity Mortality nucleocapsid Nucleocapsids pandemic Pandemics Participation Pathogens Population Regions Russia SARS-CoV-2 Serology seroprevalence Severe acute respiratory syndrome coronavirus 2 Volunteers |
SummonAdditionalLinks | – databaseName: Health & Medical Collection (Proquest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3faxQxEA5aEXwp_sTTKlF88CV0k80mmyepp6UKaunZcviyJJtJLehu2-sJ_vfO7O6tLkhfN8MSJjOT-ZLJN4y9yp0ppZUgfBm00NrnImQuEzG3PqW8xqBI750_fTYHx_rjslgOB26roaxyExO7QB3bms7IdxXdzynMZ82b8wtBXaPodnVooXGT3SLqMgJfdjkCLkPIr2cTyhHa7_7CeF0iPCgne1BH1T_JL6fVkf9sN_t32faQJ_K9fmHvsRvQ3Ge3-86Rvx-wb4u9o4WYtydCcXR3amWCJkNeyhcdI-z6EnibOKZ3_Gi9opeS_HDs1cX7x4nd6PzLyYd3Qjp-SMfJP8_qh-x4__3X-YEY2iSIWlt3JcAbH0AC5nbSQYIcjK1jygrIrVM-2RqMkhjHvLXRq1A4LcuoIiQLJiEQfcS2mraBx4ybmJzWhYplAF1oHTCp1XWogwfpla9n7PVGcVU9cIhTK4sfFWIJ0nE16njGXo6i5z1xxv-E3pL2RwHiuu4-tJen1eA6VXREn6sMkUnqGBUmGNZn0qeoQyYhm7GdzdpVgwOuqr_mMmMvxmF0HboP8Q20607GZJrqb6-RMbmxGkEi_sdO7GIy6elIc_a9I-pG8KxsIZ9cP8Gn7I6iQhni2XU7bAutBJ5hpnMVnnfm_AdoBAAc priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVKERIXxKdYKMggDlwMsePY8QGhslAVpELVZauKS2THY6hUknbbRfTfM5PNRkSqOHFdj6LdyYz93tp-j7EXuTOltBKEL4MWWvtchMxlIubWp5TXOCnSfee9z2Z3rj8dFUcbbO2x2Sfw_EpqR35S88XJq99nl2-x4d8Q40TK_voXzsMlwv7yGruOC5IlB4c9PWwmGCKAK1GhcfhoKeoU-0cwc3xI8q9VZ-c2u9XDRb69er932AY0d9mNlYHk5T32bbZ9MBPT9lAojl1PjiZYOdSsfNYJwy4XwNvEEeXxg-U5XZjk-4NlF1_dUexGp18OP74X0vF9-lf553F9n813Pnyd7oreLUHU2roLAd74ABIQ4kkHCXIwto4pKyC3TvlkazBK4nTmrY1ehcJpWUYVIVkwCfnoA7bZtA08ZNzE5LQuVCwD6ELrgNhW16EOHqRXvp6wl-vEVXUvJU6OFicVUgrKcTXkeMKeD6GnK_2Mq4LeUfaHAJK87j5oF9-rvoOq6EhFVxnSlNQxKsQZ1mfSp6hDJiGbsK31u6vWZVQp2tXFeGcm7NkwjB1E2yK-gXbZxZhM0zHcf8SY3FiNXBGfY0d1MfrS45Hm-Een140cWtlCPvofv_Ixu6noVA2J8rottom1BE8QFl2Ep13R_wHL_Q5L priority: 102 providerName: Scholars Portal |
Title | SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic |
URI | https://www.proquest.com/docview/2565720496 https://www.proquest.com/docview/2566041992 https://www.proquest.com/docview/2636746256 https://pubmed.ncbi.nlm.nih.gov/PMC8402751 https://doaj.org/article/d9653926ac204dd28537a01afd4b01e0 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgCIkL4lMslJVBHLhYjR3Hjo_t0lKQWla7tFpxiex4rFaCLKJdJP49M0k2aiQEFy4-xKPImfF45sX2G8be5M6U0koQvgxaaO1zETKXiZhbn1Je46JI951PTs3xmf64KlY3Sn3RmbCOHrhT3F50RJ6qDFEJ6hgVhhfrM-lT1CGT0KJ1jHlbMNWtwYYwX8cjlCOo3_uJK3WJwKAcRZ-WpH-UWY7PRd4INEcP2P0-Q-T73cgeslvQPGJ3u5qRvx6zL8v9xVLM1udCcXR0KmKCk4X8ky9bLtjND-DrxDGx44vNFd2R5POhShfvriW2vbNP5x_eCen4nH4kf7usn7Czo8PPs2PRF0gQtbbuWoA3PoAEzOqkgwQ5GFvHlBWQW6d8sjUYJXEF89ZGr0LhtCyjipAsmIQQ9CnbadYNPGPcxOS0LlQsA-hC64DprK5DHTxIr3w9YW-3iqvqnj2cilh8rRBFkI6rQccT9noQ_d5RZvxJ6IC0PwgQy3X7AG1f9bav_mX7Cdvd2q7qXe-qUrSRi_LOTNiroRudhnZCfAPrTStjMk0nb_8iY3JjNcJDfI8dzYvRoMc9zeVFS9GNsFnZQj7_H1_5gt1TdJCGeHjdLtvBuQQvMRO6DlN2267slN05ODydL6atC2D7fiWxPdHlb-W9DHI |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgQXxFMsFDAIJC5WY8ex4wNCZUu1Sx9U3bZacQmO7UAlSEq3C-qf4jcykxdEQr31Go8iazxPe-YbQl7GRqVc88BsmksmpY1ZHpmI-VjboogdGEXsd97dU5Mj-WGezFfI764XBssqO5tYG2pfObwjXxf4PicgnlVvT38wnBqFr6vdCI1GLLbDxS9I2RZvpptwvq-E2Hp_OJ6wdqoAc1KbcxassnngAUIhbkIR4qC080WUhFgbYQvtghIc1N5q7a3IEyN56oUPhQ6qSBDoAEz-NXC8EZYQ6nmf4CnMNBv0ojg20fpP8A8ppCPpwOfVowEG8eywGvMf97Z1m9xq41K60QjSHbISyrvkejOp8uIe-TTbOJixcXXMBAXzgqNTQETRKtBZjUC7PAu0KiiEk_RgucDOTLrfzwajTTNkvTr-eDzdZNzQfby-_n7i7pOjK2HgA7JaVmV4SKjyhZEyET7Ng0ykzCGIli53uQ3cCutG5HXHuMy1mOU4OuNbBrkL8jjreTwiL3rS0wao439E75D7PQFia9cfqrMvWauqmTcI1ysUgldK7wUENNpG3BZe5hEP0YisdWeXtQq_yP6K54g875dBVfH9xZahWtY0KpJY73sJjYqVlpCUwn_0QC4Gmx6ulCdfa2BwSNaFTvijyzf4jNyYHO7uZDvTve3H5KbAIh3E-DVrZBUkJjyBKOs8f1qLNiWfr1qX_gCbyz93 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIRAviE9RGGAQSLxYjR3Hjh8QGi3VymBUK5uqvQQntmESJGNdQfvX-Ou4S9JAJLS3vcanyDrfp333O0Kex0alXHPPbJpLJqWNWR6ZiLlY2xDiAowi9jt_2FM7B_LdIllskN_rXhgsq1zbxNpQu6rAO_KhwPc5AfGsGoa2LGI2nrw--cFwghS-tK7HaTQisuvPf0H6tnw1HcNZvxBi8vbTaIe1EwZYIbU5Y94qm3vuISzixgcfe6ULF6LEx9oIG3ThleBgAqzWzoo8MZKnTjgftFchQdADMP9XdAxuE3RJL7pkT2HW2SAZxbGJhj_BV6SQmqQ9_1ePCejFtv3KzH9c3eQmudHGqHS7EapbZMOXt8nVZmrl-R1yNN_en7NRdcgEBVODY1RAXNFC0HmNRrs69bQKFEJLur9aYpcmnXVzwmjTGFmvjj4eTseMGzrDq-zvx8VdcnApDLxHNsuq9PcJVS4YKRPh0tzLRMocAmpZ5EVuPbfCFgPycs24rGjxy3GMxrcM8hjkcdbxeECedaQnDWjH_4jeIPc7AsTZrj9Up1-yVm0zZxC6VygEspTOCQhutI24DU7mEffRgGytzy5rlX-Z_RXVAXnaLYPa4luMLX21qmlUJLH29wIaFSstIUGF_-ieXPQ23V8pj7_WIOGQuAud8AcXb_AJuQZalL2f7u0-JNcF1usg3K_ZIpsgMP4RBFxn-eNasin5fNmq9AccE0Ot |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+Seroprevalence+Structure+of+the+Russian+Population+during+the+COVID-19+Pandemic&rft.jtitle=Viruses&rft.au=Anna+Y.+Popova&rft.au=Viacheslav+S.+Smirnov&rft.au=Elena+E.+Andreeva&rft.au=Elena+A.+Babura&rft.date=2021-08-19&rft.pub=MDPI+AG&rft.eissn=1999-4915&rft.volume=13&rft.issue=8&rft.spage=1648&rft_id=info:doi/10.3390%2Fv13081648&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d9653926ac204dd28537a01afd4b01e0 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4915&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4915&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4915&client=summon |